Exchange: NASDAQ·Updated 07:59 PM EST

SPRC News

News
all
press releases
Ants, Spiders, Robots and Seats: Anthropic's IPO Could Put These Stocks in the Spotlight
From artificial intelligence and genetically engineered spider silk to intelligent robotics and a heavily indebted ticket marketplace, an unusual group of smaller publicly traded companies could find themselves riding the same wave of investor enthusiasm. Anthropic's (NASDAQ:ANT) highly anticipated November 19 IPO, reportedly priced at $83 per share with demand exceeding available shares by as much as six times, is putting the spotlight on the enormous commercial potential of emerging technologies. That attention could spill over to GMEX Robotics (NASDAQ:GMEX), Kraig Biocraft Laboratories (OTCQB:KBLB), SciSparc (NASDAQ:SPRC), Global Mofy AI (NASDAQ:GMM), Greenlane Holdings (NASDAQ:GNLN), and Vivid Seats (NASDAQ:SEAT). Their stories are far from identical, but each offers a different angle on the innovation, investment and corporate transformations that could attract investors as Anthropic's arrival reshapes the public-market conversation around technology.
24-7 Market News
Ants, Spiders, Robots and Seats: Anthropic's IPO Could Put These Stocks in the Spotlight
From artificial intelligence and genetically engineered spider silk to intelligent robotics and a heavily indebted ticket marketplace, an unusual group of smaller publicly traded companies could find themselves riding the same wave of investor enthusiasm. Anthropic's (NASDAQ:ANT) highly anticipated November 19 IPO, reportedly priced at $83 per share with demand exceeding available shares by as much as six times, is putting the spotlight on the enormous commercial potential of emerging technologies. That attention could spill over to GMEX Robotics (NASDAQ:GMEX), Kraig Biocraft Laboratories (OTCQB:KBLB), SciSparc (NASDAQ:SPRC), Global Mofy AI (NASDAQ:GMM), Greenlane Holdings (NASDAQ:GNLN), and Vivid Seats (NASDAQ:SEAT). Their stories are far from identical, but each offers a different angle on the innovation, investment and corporate transformations that could attract investors as Anthropic's arrival reshapes the public-market conversation around technology.
24-7 Market News
More News
SciSparc shares jump 38.87% after hours following an AI and cybersecurity advisory board appointment amid heightened trading volume.read more...
Benzinga
Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC) shares roseread more...
Benzinga
These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.
24-7 Market News
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9read more...
Benzinga
Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.read more...
Benzinga
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 28.9% to $4.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 million. Valion Bio (NASDAQ:VBIO) stock increasedread more...
Benzinga
SciSparc (NASDAQ:SPRC) is making its ambitions clear: the company wants to move beyond its traditional cannabinoid-based pharmaceutical business and explore the rapidly developing market for agentic artificial intelligence, with cybersecurity and financial technology emerging as key targets.
24-7 Market News
The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX
24-7 Market News
Healthcare and biotechnology remain especially active and offer asymmetric upside potential, as companies pursue international expansion, strategic refinancing, AI-driven operational efficiency, and next-generation pharmaceutical technologies. $TGNT, $SPRC, $WGRX, $ATPC, $SNYR, $PHR
24-7 Market News

Advertisement|Remove ads.